Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 21 to 75~* Biopsy-confirmed NASH with fibrosis stage F2 or F3 per NASH CRN System and NAS ≥4, with a score of at least 1 in each of steatosis, ballooning degeneration, and lobular inflammation.~  * Qualifying biopsy must be either within 6 months of screening visit or obtained during screening period~Key Exclusion Criteria:~* Have poorly controlled high blood pressure~* Have type 1 diabetes or poorly controlled type 2 diabetes.~* History of cirrhosis or evidence of cirrhosis by clinical, imaging or liver biopsy evaluation~* Are planning to try to lose weight during the conduct of the study.~* Have a BMI \<25 kg/m2~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BIO89-100 - 15 mg once weekly (QW) (Type: EXPERIMENTAL): BIO89-100 - 15 mg QW
- BIO89-100 - 30 mg QW (Type: EXPERIMENTAL): BIO89-100 - 30 mg QW
- BIO89-100 - 44 mg once every 2 weeks (Q2W) (Type: EXPERIMENTAL): BIO89-100 - 44 mg Q2W
- Placebo QW (Type: PLACEBO_COMPARATOR): Placebo QW
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Placebo Q2W
- Placebo QW (Main study)/ BIO89-100 - 30 mg QW (Extension) (Type: EXPERIMENTAL): Placebo QW (Main study)/ BIO89-100 - 30 mg QW (Extension)

Based on this trial design, predict the completion outcome and termination type (if applicable).